The latest from DTC Perspectives

After the FDA Hearings - An Exclusive Report by DTC INSIGHTS

DTC Perspectives, with exclusive support from HealthCentral, launches "After the FDA Hearings" a microsite featuring special reports on the data, testimony and speakers comments, outlook for FDA action.

DTC Perspectives, with exclusive support from HealthCentral, launches

"After the FDA Hearings"

a microsite featuring special reports on the data, testimony and speakers comments, outlook for FDA action.

Reports Include :
-Expert Analysis by Christopher Schroeder, CEO, HealthCentral
-Hearings Review by Mark Tosh, Editor-in-Chief, DTC Perspectives DDMAC's Abrams Promises ‘Careful' Review of Presentations
-Eli Lilly Looking For More ‘Clarity' From FDA
-Lack of Clarity for Online Ads Creates Confusion
-Consumers Want, Expect Pharma To Participate in Social Media
-Consumers Seek Health, Safety Information Through Online and Social Media Channels
-comScore Survey: 50% of Health-Info Seekers Use Social Media to Find Health Information
- One-Click' Rule Is Not Good Regulatory Policy

The message from marketers and media experts rang clear at last week's FDA hearings: communication with patients and healthcare professionals has drastically changed since the FDA first allowed mass broadcast DTC advertising more than a decade ago. Speaker after speaker – with just a few exceptions – told FDA that the pharmaceutical industry and companies in the new-media sector need more clarity from the agency, either in terms of new guidance or executive direction, so that these new communication channels can be used by pharma to improve health outcomes and patient care.

The FDA offered an open ear and promised a careful review of the testimony as it wrestles with this revolution in communication – and at a time when healthcare is a high priority of the Obama Administration.

DTC Perspectives has teamed with HealthCentral, an online resource offering 35 condition- and wellness-specific interactive health sites for consumers, to produce a special report on the two-day hearings, held Nov. 12-13 in Washington, that highlights just a few of the 75-plus speaker presentations and provides an analysis / overview of the important issue of how pharma can best use the Internet and social media.

To access reports, please click here

To add to the conversation and continue monitoring this issue, use the Twitter hash tag: #FDASM